Phase I and preliminary phase II studies on aclacinomycin A in patients with acute leukemia

Hisamitsu Suzuki; Kohei Kawashima; Kazumasa Yamada; Saburo Minami; Yukio Kato; Mitsune Tanimoto; Hironori Yamada; Kenichi Isobe; Kiyotaka Hayashi; Hiroshi Yamaguchi; Junki Takamatsu; Eiji Watanabe; Yoshihisa Kodera; Hiroshi Shiku; Tadashi Kamiya; Ryuzo Ohno; Hiroshi Morishita; Shozo Yokomaku; Kazuko Yoshida; Michinori Ogura

Phase I and preliminary phase II studies on aclacinomycin A in patients with acute leukemia

Hisamitsu Suzuki, Kohei Kawashima, Kazumasa Yamada, Saburo Minami, Yukio Kato, Mitsune Tanimoto, Hironori Yamada, Kenichi Isobe, Kiyotaka Hayashi, Hiroshi Yamaguchi, Junki Takamatsu, Eiji Watanabe, Yoshihisa Kodera, Hiroshi Shiku, Tadashi Kamiya, Ryuzo Ohno, Hiroshi Morishita, Shozo Yokomaku, Kazuko Yoshida, Michinori Ogura

Graduate School of Medicine Dentistry and Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Eight patients with acute nonlymphocytic leukemia (ANLL) and five patients with acute lymphocytic leukemia were treated with aclacinomycin A. It was given daily by one-hour infusion in doses ranging from 0.33 to 0.70 mg/kg for seven to 20 days without other antileukemic agents. Two patients with ANLL achieved complete remission and one with ANLL achieved partial remission. Its major toxic effects were myelosuppression and gastrointestinal symptoms.

Original language	English
Pages (from-to)	111-118
Number of pages	8
Journal	Japanese journal of clinical oncology
Volume	10
Issue number	1
Publication status	Published - Jun 1980

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Suzuki, H., Kawashima, K., Yamada, K., Minami, S., Kato, Y., Tanimoto, M., Yamada, H., Isobe, K., Hayashi, K., Yamaguchi, H., Takamatsu, J., Watanabe, E., Kodera, Y., Shiku, H., Kamiya, T., Ohno, R., Morishita, H., Yokomaku, S., Yoshida, K., & Ogura, M. (1980). Phase I and preliminary phase II studies on aclacinomycin A in patients with acute leukemia. Japanese journal of clinical oncology, 10(1), 111-118.

Suzuki, H, Kawashima, K, Yamada, K, Minami, S, Kato, Y, Tanimoto, M, Yamada, H, Isobe, K, Hayashi, K, Yamaguchi, H, Takamatsu, J, Watanabe, E, Kodera, Y, Shiku, H, Kamiya, T, Ohno, R, Morishita, H, Yokomaku, S, Yoshida, K & Ogura, M 1980, 'Phase I and preliminary phase II studies on aclacinomycin A in patients with acute leukemia', Japanese journal of clinical oncology, vol. 10, no. 1, pp. 111-118.

@article{e2b2f1348e00417fbc62bf80147604ce,

title = "Phase I and preliminary phase II studies on aclacinomycin A in patients with acute leukemia",

abstract = "Eight patients with acute nonlymphocytic leukemia (ANLL) and five patients with acute lymphocytic leukemia were treated with aclacinomycin A. It was given daily by one-hour infusion in doses ranging from 0.33 to 0.70 mg/kg for seven to 20 days without other antileukemic agents. Two patients with ANLL achieved complete remission and one with ANLL achieved partial remission. Its major toxic effects were myelosuppression and gastrointestinal symptoms.",

author = "Hisamitsu Suzuki and Kohei Kawashima and Kazumasa Yamada and Saburo Minami and Yukio Kato and Mitsune Tanimoto and Hironori Yamada and Kenichi Isobe and Kiyotaka Hayashi and Hiroshi Yamaguchi and Junki Takamatsu and Eiji Watanabe and Yoshihisa Kodera and Hiroshi Shiku and Tadashi Kamiya and Ryuzo Ohno and Hiroshi Morishita and Shozo Yokomaku and Kazuko Yoshida and Michinori Ogura",

note = "Funding Information: Aclacinomycin A is a new anthracycline antibiotic isolated from Streptomyces gali-laeus by Umezawa and his colleagues (Oki et al., 1975). This compound consists of aglycone, aklavinone and a trisaccharide moiety, rhodosamine, 2-deoxyfucose and L-cinerulose (Oki, 1977). In preclinical studies aclacinomycin A has been reported to be active against several animal tumor models including murine leukemias L-1210 and P-388 and some solid tumors (Oki, Received March 8, 1980. This work is supported in part by Grants-in-Aid for Cancer Research (54-5) from the Ministry of Health and Welfare of Japan. Reprint request: Hisamitsu Suzuki, M.D, First Department of Internal Medicine, Nagoya University School of Medicine, Tsurumai-cho, Showa-ku, Nagoya, Japan. Copyright: Copyright 2010 Elsevier B.V., All rights reserved.",

year = "1980",

month = jun,

language = "English",

volume = "10",

pages = "111--118",

journal = "Japanese journal of clinical oncology",

issn = "0368-2811",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Phase I and preliminary phase II studies on aclacinomycin A in patients with acute leukemia

AU - Suzuki, Hisamitsu

AU - Kawashima, Kohei

AU - Yamada, Kazumasa

AU - Minami, Saburo

AU - Kato, Yukio

AU - Tanimoto, Mitsune

AU - Yamada, Hironori

AU - Isobe, Kenichi

AU - Hayashi, Kiyotaka

AU - Yamaguchi, Hiroshi

AU - Takamatsu, Junki

AU - Watanabe, Eiji

AU - Kodera, Yoshihisa

AU - Shiku, Hiroshi

AU - Kamiya, Tadashi

AU - Ohno, Ryuzo

AU - Morishita, Hiroshi

AU - Yokomaku, Shozo

AU - Yoshida, Kazuko

AU - Ogura, Michinori

N1 - Funding Information: Aclacinomycin A is a new anthracycline antibiotic isolated from Streptomyces gali-laeus by Umezawa and his colleagues (Oki et al., 1975). This compound consists of aglycone, aklavinone and a trisaccharide moiety, rhodosamine, 2-deoxyfucose and L-cinerulose (Oki, 1977). In preclinical studies aclacinomycin A has been reported to be active against several animal tumor models including murine leukemias L-1210 and P-388 and some solid tumors (Oki, Received March 8, 1980. This work is supported in part by Grants-in-Aid for Cancer Research (54-5) from the Ministry of Health and Welfare of Japan. Reprint request: Hisamitsu Suzuki, M.D, First Department of Internal Medicine, Nagoya University School of Medicine, Tsurumai-cho, Showa-ku, Nagoya, Japan. Copyright: Copyright 2010 Elsevier B.V., All rights reserved.

PY - 1980/6

Y1 - 1980/6

N2 - Eight patients with acute nonlymphocytic leukemia (ANLL) and five patients with acute lymphocytic leukemia were treated with aclacinomycin A. It was given daily by one-hour infusion in doses ranging from 0.33 to 0.70 mg/kg for seven to 20 days without other antileukemic agents. Two patients with ANLL achieved complete remission and one with ANLL achieved partial remission. Its major toxic effects were myelosuppression and gastrointestinal symptoms.

AB - Eight patients with acute nonlymphocytic leukemia (ANLL) and five patients with acute lymphocytic leukemia were treated with aclacinomycin A. It was given daily by one-hour infusion in doses ranging from 0.33 to 0.70 mg/kg for seven to 20 days without other antileukemic agents. Two patients with ANLL achieved complete remission and one with ANLL achieved partial remission. Its major toxic effects were myelosuppression and gastrointestinal symptoms.

UR - http://www.scopus.com/inward/record.url?scp=77957210697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957210697&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77957210697

SN - 0368-2811

VL - 10

SP - 111

EP - 118

JO - Japanese journal of clinical oncology

JF - Japanese journal of clinical oncology

IS - 1

ER -

Phase I and preliminary phase II studies on aclacinomycin A in patients with acute leukemia

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this